Please check your internet connection and try again.
# Meftal-Spas
## Overview
Meftal-Spas is a fixed-dose combination medication containing **Mefenamic Acid** (an NSAID; 250 mg) and **Dicyclomine Hydrochloride** (an antispasmodic; 10 mg).
## Primary Indications
* Symptomatic relief of spasmodic dysmenorrhea (primary).
* Abdominal cramps and pain associated with gastrointestinal hypermotility.
* Musculoskeletal pain and mild-to-moderate inflammatory conditions.
## Adult Dosing
* **Standard Dose:** 1 tablet (250 mg Mefenamic Acid / 10 mg Dicyclomine) taken orally 3 to 4 times daily.
* **Maximum Dose:** Do not exceed 4 tablets in 24 hours. Limit therapy duration to the shortest period necessary (usually < 7 days).
## Pediatric Dosing
* **Safety Warning:** Generally not recommended for children under 12 years of age due to lack of established safety and efficacy data for this specific combination. Use in adolescents should be supervised by a clinician.
## Dose Adjustments
* **Renal Impairment:** Avoid in severe renal impairment. Use with extreme caution in mild-to-moderate impairment; monitor creatinine clearance and fluid balance.
* **Hepatic Impairment:** Avoid in patients with active liver disease.
* **Geriatric:** Use with caution; increased risk of NSAID-related gastrointestinal bleeding and anticholinergic effects (confusion, urinary retention, sedation).
## Contraindications
* Known hypersensitivity to Mefenamic Acid, Dicyclomine, or other NSAIDs.
* History of asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs.
* Active gastrointestinal ulceration or inflammatory bowel disease.
* History of CABG surgery (peri-operative pain).
* Severe heart failure.
* Glaucoma, myasthenia gravis, or obstructive uropathy.
## Adverse Effects
* **NSAID-related:** Gastritis, gastrointestinal ulceration, dyspepsia, potential for cardiovascular events (thrombosis), and renal toxicity.
* **Anticholinergic (Dicyclomine):** Xerostomia (dry mouth), blurred vision, constipation, dizziness, urinary retention, and tachycardia.
## Key Drug Interactions
* **Anticoagulants (e.g., Warfarin):** Increases risk of bleeding.
* **Lithium/Methotrexate:** NSAIDs increase plasma concentrations/toxicity risk.
* **Antipsychotics/Tricyclic Antidepressants:** May potentiate anticholinergic effects of Dicyclomine.
* **Antihypertensives (ACE inhibitors/Diuretics):** NSAIDs may reduce therapeutic efficacy and increase risk of acute kidney injury.
## Monitoring
* Monitor for signs of GI bleeding (occult blood, anemia).
* Monitor renal function (BUN/SCr) in long-term or high-risk patients.
* Monitor blood pressure during treatment.
* Assess for anticholinergic toxicity (especially urinary retention in elderly patients).
## Clinical Pearls
* **Administration:** Take with food or milk to minimize gastric irritation.
* **Alcohol:** Avoid alcohol, as it may enhance sedation from Dicyclomine and gastric irritation from Mefenamic Acid.
* **Uncertainty:** Dosing protocols can vary by region and specific formulation; always follow local regulatory labeling or institutional guidelines.
* **Emergency:** Discontinue immediately if any signs of a hypersensitivity reaction (rash, wheezing) occur.
***
**Educational Disclaimer:** This information is provided for educational purposes only. Drug information is subject to frequent updates. Always verify exact dosing, contraindications, and drug interactions using current, localized prescribing information (e.g., electronic drug databases or the manufacturer's package insert) before prescribing or administering medication. Consult a licensed physician or pharmacist for clinical decision-making.
